# Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

> **NCT00099489** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 67 (—)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy

## Interventions

- **DRUG:** Interferon Beta-1a

## Key facts

- **NCT ID:** NCT00099489
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 67 (—)
- **Last updated:** 2010-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099489, "Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00099489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*